Literature DB >> 11055039

Personal values and cancer treatment refusal.

M Huijer1, E van Leeuwen.   

Abstract

This pilot study explores the reasons patients have for refusing chemotherapy, and the ways oncologists respond to them. Our hypothesis, generated from interviews with patients and oncologists, is that an ethical approach that views a refusal as an autonomous choice, in which patients are informed about the pros and cons of treatment and have to decide by weighing them, is not sufficient. A different ethical approach is needed to deal with the various evaluations that play a role in treatment refusal. If patients forgo further treatment, while curative or palliative methods are available, there is no perspective from which to integrate the weighing of pros and cons of treatment and the preferences and values of individual cancer patients. A discrepancy thus results as regards what "good reasons" are, evoking misunderstandings or even breaking off communication. Suggestions are given for follow up research.

Entities:  

Keywords:  Empirical Approach; Professional Patient Relationship

Mesh:

Year:  2000        PMID: 11055039      PMCID: PMC1733299          DOI: 10.1136/jme.26.5.358

Source DB:  PubMed          Journal:  J Med Ethics        ISSN: 0306-6800            Impact factor:   2.903


  13 in total

1.  When competent patients make irrational choices.

Authors:  D W Brock; S A Wartman
Journal:  N Engl J Med       Date:  1990-05-31       Impact factor: 91.245

2.  Factors affecting treatment decisions for a life-threatening illness: the case of medical treatment of breast cancer.

Authors:  L A Siminoff; J H Fetting
Journal:  Soc Sci Med       Date:  1991       Impact factor: 4.634

3.  Relationship between cancer patients' predictions of prognosis and their treatment preferences.

Authors:  J C Weeks; E F Cook; S J O'Day; L M Peterson; N Wenger; D Reding; F E Harrell; P Kussin; N V Dawson; A F Connors; J Lynn; R S Phillips
Journal:  JAMA       Date:  1998-06-03       Impact factor: 56.272

Review 4.  Clinical aspects of cancer in the elderly. Treatment decisions, treatment choices, and follow-up.

Authors:  R J McKenna
Journal:  Cancer       Date:  1994-10-01       Impact factor: 6.860

5.  Autonomy, religious values, and refusal of lifesaving medical treatment.

Authors:  M J Wreen
Journal:  J Med Ethics       Date:  1991-09       Impact factor: 2.903

6.  It's ok to say no! A discussion of ethical issues arising from informed consent to chemotherapy.

Authors:  P McGrath
Journal:  Cancer Nurs       Date:  1995-04       Impact factor: 2.592

7.  Ethical considerations in oncology: balancing the interests of patients, oncologists, and society.

Authors:  T J Smith; J N Bodurtha
Journal:  J Clin Oncol       Date:  1995-09       Impact factor: 44.544

8.  Relationship between preferences for decisional control and illness information among women with breast cancer: a quantitative and qualitative analysis.

Authors:  T F Hack; L F Degner; D G Dyck
Journal:  Soc Sci Med       Date:  1994-07       Impact factor: 4.634

9.  Attitudes to chemotherapy: comparing views of patients with cancer with those of doctors, nurses, and general public.

Authors:  M L Slevin; L Stubbs; H J Plant; P Wilson; W M Gregory; P J Armes; S M Downer
Journal:  BMJ       Date:  1990-06-02

10.  Information needs, sources of information, and decisional roles in women with breast cancer.

Authors:  B A Bilodeau; L F Degner
Journal:  Oncol Nurs Forum       Date:  1996-05       Impact factor: 2.172

View more
  13 in total

1.  Doc, I don't want your poison.

Authors:  Francesca Giorgi; Romeo Bascioni
Journal:  Oncologist       Date:  2012-06-11

2.  Physicians' evaluations of patients' decisions to refuse oncological treatment.

Authors:  T van Kleffens; E van Leeuwen
Journal:  J Med Ethics       Date:  2005-03       Impact factor: 2.903

3.  Clinical and economic burden associated with stage III to IV triple-negative breast cancer: A SEER-Medicare historical cohort study in elderly women in the United States.

Authors:  Kendra L Schwartz; Michael S Simon; Lauren C Bylsma; Julie J Ruterbusch; Jennifer L Beebe-Dimmer; Neil M Schultz; Scott C Flanders; Arie Barlev; Jon P Fryzek; Ruben G W Quek
Journal:  Cancer       Date:  2018-03-05       Impact factor: 6.860

4.  Personhood within the context of sedation at the end of life in Singapore.

Authors:  Lalit Kumar Radha Krishna
Journal:  BMJ Case Rep       Date:  2013-06-07

5.  Risk, Activism, and Empowerment: Women's Breast Cancer in Venezuela.

Authors:  Mahmoud Eid; Isaac Nahon-Serfaty
Journal:  Int J Civ Engagem Soc Change       Date:  2015-01-01

6.  Characteristics of older newly diagnosed cancer patients refusing cancer treatments.

Authors:  Martine T E Puts; Johanne Monette; Veronique Girre; Christina Wolfson; Michèle Monette; Gerald Batist; Howard Bergman
Journal:  Support Care Cancer       Date:  2010-04-25       Impact factor: 3.603

7.  Seeking Mind, Body and Spirit Healing-Why Some Men with Prostate Cancer Choose CAM (Complementary and Alternative Medicine) over Conventional Cancer Treatments.

Authors:  Margaret A White; Marja J Verhoef; B J Davison; Hal Gunn; Karen Cooke
Journal:  Integr Med Insights       Date:  2008-02-01

Review 8.  Culture and end of life care: a scoping exercise in seven European countries.

Authors:  Marjolein Gysels; Natalie Evans; Arantza Meñaca; Erin Andrew; Franco Toscani; Sylvia Finetti; H Roeline Pasman; Irene Higginson; Richard Harding; Robert Pool
Journal:  PLoS One       Date:  2012-04-03       Impact factor: 3.240

9.  Declining conventional cancer treatment and using complementary and alternative medicine: a problem or a challenge?

Authors:  M J Verhoef; M S Rose; M White; L G Balneaves
Journal:  Curr Oncol       Date:  2008-08       Impact factor: 3.677

10.  Factors associated with lung cancer patients refusing treatment and their survival: a national cohort study under a universal health insurance in Taiwan.

Authors:  Hsiu-Ling Huang; Pei-Tseng Kung; Chang-Fang Chiu; Yueh-Hsin Wang; Wen-Chen Tsai
Journal:  PLoS One       Date:  2014-07-07       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.